Bladder Cell Cancer Algorithm Discussion with Andrea Apolo
Andrea Apolo , MD, Chief of Bladder Cancer - Genitourinary Malignancy at the National Cancer Institute, shares her approach to treating bladder cancer as the field continues to evolve following the outcomes of phase III trials.
Bladder cell cancer algorithm explained by Dr. Andrea Apolo . Learn about diagnosis, treatment options, and research advancements.
Bladder Cell Cancer Algorithm Discussion with Dr. Andrea Apolo ...
Listen to this episode of Oncology Brothers for free on iVoox. Discussing the management of Bladder Cancer using an algorithm - with Dr. Andrea Apolo , Chief of Bladder Cancer - Genitourinary Malignancy at the...
Discussing the management using the algorithm of Bladder Cancer - with Dr. Andrea Apolo , Chief of Bladder Cancer - Genitourinary Malignancy at the National Cancer Institute.
Andrea Apolo Highlights the Top 5 Clinical Advances in Bladder Cancer ...
Andrea Apolo Highlights the Top 5 Clinical Advances in Bladder Cancer Treatment for 2024 American Cancer Society Journals shared on LinkedIn: "The outlook for the Bladder Cancer field is undoubtedly positive as the field builds upon an excellent foundation of novel therapeutics and drug delivery mechanisms.
Andrea B. Apolo , M.D., is an internationally recognized expert in bladder cancer research. She was recruited to the National Cancer Institute's (NCI's) Physician-Scientist Early Investigator Program in 2010 to build a translational bladder cancer program.
Bridging Evidence to Practice
Ashish Kamat talks with Andrea Apolo about implementing new treatment standards in bladder cancer , focusing on the recent EV-302 and CheckMate-901 trials. Dr. Apolo explains how enfortumab vedotin plus pembrolizumab has emerged as the new standard of care for metastatic urothelial carcinoma, showing superior survival outcomes compared to traditional platinum-based chemotherapy. They explore the...
Dr. Apolo noted that a phase 3 study is currently being developed and may provide important opportunities for biomarker discovery and future bladder -preservation strategies. Implications for the Evolving Treatment Algorithm Dr. Apolo concluded by integrating these findings into the evolving urothelial carcinoma treatment landscape.
Final Results From a Phase I Trial and Expansion Cohorts of ...
We report an overall response rate of 38%, with notable efficacy in rare tumor types, such as penile carcinoma, bladder adenocarcinoma, and squamous cell bladder cancer , that lack treatment options. Our immune cell subset correlates show differential immunomodulation between CaboNivo and CaboNivoIpi. This trial has prompted several larger trials in multiple GU tumors, including a larger phase ...
This review highlights the top advances in nonmuscle-invasive, muscle-invasive, and metastatic bladder cancer over the past year. The outlook for the field is undoubtedly positive as the field builds...